Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HWX0101
- Development stage
- Unknown
- Lead developer
- Jiangsu Kanion Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HWX0101 is a small molecule calcium channel blocker (CCB) being developed by Kanion Pharmaceutical and Huawe Medicine. It is currently in Phase 1 clinical development for the treatment of hypertension and the prevention of recurrent intracerebral hemorrhage (ICH). As a next-generation CCB, it is designed for high vascular selectivity and a long duration of action, aiming to provide stable blood pressure control and neurovascular protection. The drug is classified as a Class 1 innovative drug in China, and the sponsor holds development rights in both China and the United States.
- Other names
- HWX0101HWX-0101HWX 0101
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on HWX0101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HWX0101.